Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 6 months and under 18 years (or under 30 for one study part) when you sign consent.
- Your lymphoma has been confirmed on tissue/biopsy or fluid sample and it shows CD20 on the tumor cells.
- Your cancer must be relapsed (came back) or refractory (didn’t respond), and you’ve had the required number of prior standard treatments for your study group.
- You must have measurable lymphoma (a lymph node/spot large enough, or measurable bone marrow involvement).
- Your overall activity level is sufficient (Lansky/Karnofsky score meeting the study cutoff).
- Recent blood tests must show your bone marrow, liver, and kidneys can handle study treatment; also you must be negative for hepatitis B/C and be HIV-negative (with limited exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
This trial tests two new treatment combinations for children and young adults with B-cell non-Hodgkin lymphoma that has come back or not responded to previous therapy. The goal is to find better options for treating this cancer.
This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This Phase 2 study tests how well obinutuzumab (an antibody medicine) combined with chemotherapy works for people whose CD20-positive B-cell lymphoma has come back or didn’t respond to initial treatment. It may help by attacking lymphoma cells that carry the CD20 marker.
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Hear when a new Mature B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.